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Abstract
Background: Following our previous publication we have received critical comments to our
conclusions as well as new data that are strengthening our findings.
Results: With the new data, 11 suicide attempts among patients on paroxetine against 1 among
patients on placebo, we found with a Bayesian technique that the posterior probability that
medication with paroxetine is associated with an increased intensity per year of a suicide attempt
is from 0.98 to 0.99, depending on the prior.
We found that the comment to our article by GSK representatives contained errors,
misunderstanding and unwillingness to accept Bayesian principles in the analysis of clinical trials.
Conclusion: We were in our previous publication, with preliminary data and a Bayesian approach,
able to raise a concern that suicide attempts might be connected with the use of paroxetine. This
suspicion has now been confirmed.
Text
Last year we wrote a paper "Suicide attempts in clinical tri-
als with paroxetine randomised against placebo" [1] that
hit the front pages of newspapers worldwide [2,3]. Our
publication demonstrated an increased intensity of sui-
cide attempts per year when using paroxetine compared to
placebo, and caused GlaxoSmithKline (GSK) to come up
with a comment [4]. Since then GSK has provided addi-
tional data to the American Food and Drug Administra-
tion (FDA), as the agency required new documentation
on paroxetine. This also resulted in a Briefing Document
from GSK [5] in which they admit that there is an
increased risk for suicide attempts associated with paroxe-
tine.
We analyzed the data GSK presented in their latest report
by the same Bayesian approach used by us in our article.
We included only the double blind, parallel design studies
with patients randomized to either paroxetine or placebo,
as recognized by GSK in the Briefing Document. These 19
studies contained 3455 and 1978 patients to the treat-
ment and placebo groups, respectively. They resulted in
11 and 1 suicide attempts, respectively, as compared to 7
and 1 in our study. The studies lasted 6 – 12 weeks, and
we obtained 601 and 333 patient years in the treatment
and placebo groups, respectively. Since we did not have
access to the points of time of censoring, we were not able
to correct for this when computing the patient years. We
took the same model approach as in our article, and refer
to it for details regarding the model. We let θp and θd be
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the mean number, or intensity, per year of a suicide
attempt for a random patient in the 19 studies in the pla-
cebo and treatment group, respectively. We performed
simulations by making 80000 random draws of θp and
θd, from their independent posterior distributions. We
computed the logarithms of the ratios θd/θp, and con-
structed posterior probability density plots by applying a
standard density estimation technique to these 80000
numbers. (The logarithm was introduced to avoid an
unwelcome feature of the density estimation method).
Note that the logarithm of the ratio θd/θp is greater than
zero whenever θd is greater than θp. Hence, we calculated
the probabilities that medication with paroxetine is asso-
ciated with an increased intensity of a suicide attempt per
year as the proportions of logarithmic ratios greater than
zero in the samples. We applied three different prior
assumptions based on earlier work by others, as described
in the article. We chose to express the pessimistic view as
equivalent to observing 0.86 events with paroxetine dur-
ing 50 patient years and 0.43 with placebo during 50
patient years, adding up to 1.29 attempts per 100 patient
years, which is similar to the observed average value for
paroxetine and placebo taken together. We based the cal-
culations on a total of only 100 patient years in the prior,
compared to 934 patient years in the real data, in order to
increase the importance of the real data over the prior
information. For the slightly optimistic and slightly pessi-
mistic priors we assigned the numbers of suicidal patients
on paroxetine and placebo per 50 patient years to be
respectively 0.58 and 0.71 and vice versa. We found that
the posterior probability that medication with paroxetine
is associated with an increased intensity per year of a sui-
cide attempt is 0.99 with the pessimistic prior, 0.98 with
the slightly optimistic prior and 0.99 with the slightly pes-
simistic prior. Hence, we can be at least 98 % sure that par-
oxetine increases suicide attempts. This is stronger
evidence than the p value equal to 0.058 given in the
Briefing Document [5]. The corresponding prior probabil-
ities were respectively 0.70, 0.44 and 0.56. See figures 1
and 2 for illustrations.
In addition to calling into question the statistical method
applied, the authors of the GSK comment denied our
findings by disputing the selection of data. They state that
"analysis was based solely on early data submitted to reg-
ulatory authorities in 1989. The studies analyzed included
only 916 paroxetine-treated patients. Today we have data
from more than 13,000 adult patients treated with parox-
etine in well-controlled clinical trials." Interestingly, GSK
has now in the Briefing Document reduced the corre-
sponding number to 3455 and also admitted that they
previously had several patients with a history of suicide
attempts from an earlier trial placed in the treatment and
placebo groups. With such a case history these patients
were more likely to attempt suicide again. They should
obviously not have been included since they blurred the
results. This can be described as 'data-drowning', and is at
least poor methodology.
One item in the comment by GSK concerns two cases that
they believe we had misplaced. One patient (no 1.12.037)
was claimed to show only suicidal ideation but has by
GSK in the Briefing Document been re-classified to repre-
sent a suicide attempt. The other patient (no 04.02.056)
Posterior intensity of suicide attempt Figure 2
Posterior intensity of suicide attempt. Distributions of 
posterior logarithmic intensity ratios log(θdrug/θplacebo) with 
three different priors.
.
Prior intensity of suicide attempt Figure 1
Prior intensity of suicide attempt. Distributions of three 
different prior (see text) logarithmic intensity ratios log(θdrug/
θplacebo) (logarithmic intensity of a suicide attempt on drug 
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was from a cross over continuation study. We do not agree
that this patient should have been excluded.
GlaxoSmithKline state in their comment to our article that
the risk may be closely related to the point of time
observed in a study, and further that they would expect to
have 6 attempts in the treatment group out of a total
events of 8. The number is more precisely 5.79. Hence,
our number 7 represents a 20.9 % increase compared to
what is expected. They apply a Fishers Exact Test, which in
our opinion is a very coarse method. Both in their earlier
report in which they applied the Mantel-Haenszel test,
and in their new analysis in the Briefing Document [5]
where they applied a so-called exact method, they do not
take the exposure time of the patients properly into
account, as we have done.
In the comment to our article it was claimed that we
should have compared a hypothesis of an increased
number of suicide attempts to one in which the rate is
identical for the treatment group and placebo group. This
hypothesis is meaningless. No one believes that the rates
for these two groups are exactly equal. Secondly, we do
not in any way attempt to do any form of hypothesis test-
ing. We are merely computing the probability that medi-
cation with paroxetine is associated with an increased
intensity per year of suicide attempts. GSK questions our
statement that '...the data strongly suggest that the use of
SSRIs is connected with an increased intensity of suicide
attempts per year'. We feel that this is all about under-
standing and accepting the Bayesian approach as a way of
analysing data. Recently FDA issued a drafted guidance for
using Bayesian statistics in clinical trials [6]. They write
'Bayesian statistics is a statistical theory and approach to
data analysis that provides a coherent method for learning
from evidence as it accumulates.' Hopefully FDA's guide-
lines will contribute to an increasing understanding of the
Bayesian approach.
We conclude that irrespective of the various prior assump-
tions, we now see clearer that the data strongly suggest
that the use of antidepressant drugs is connected with an
increased intensity of suicide attempts per year, not only
among young people, but also among adults. Moreover,
information from studies on antidepressants and other
drugs must be made open for researchers and presented in
the most informative way possible. We believe that this
would create an open minded, trusting dialogue between
consumers, manufacturers and scientists working towards
the same goal: finding the best and safest treatment for the
patients.
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